DaVita, Inc. Hits New 52-Week High at USD 157.90

DaVita, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 157.90 on February 27, 2026. This achievement marks a notable increase from its 52-week low of USD 101, reflecting a year-over-year performance of 10.4%. The company's market capitalization stands at approximately USD 11,237 million, indicating its position within the small-cap category. DaVita's price-to-earnings (P/E) ratio is currently at 9.00, which is a key metric for evaluating its valuation relative to earnings. However, the company has reported a negative return on equity of -163.56%, suggesting challenges in generating profit from shareholders' equity. Additionally, DaVita's debt-to-equity ratio is at -15.25, indicating a unique financial structure. The company does not offer a dividend yield, which is an important consideration for income-focused investors. Overall, DaVita's recent performance and current metrics highlight its evolving position in the market.